Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more
Laurus Labs Limited (LAURUSLABS) - Net Assets
Latest net assets as of September 2025: ₹49.34 Billion INR
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has net assets worth ₹49.34 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹94.15 Billion) and total liabilities (₹44.82 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹49.34 Billion |
| % of Total Assets | 52.4% |
| Annual Growth Rate | 27.09% |
| 5-Year Change | 76.97% |
| 10-Year Change | 440.32% |
| Growth Volatility | 26.92 |
Laurus Labs Limited - Net Assets Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Laurus Labs Limited (2013–2025)
The table below shows the annual net assets of Laurus Labs Limited from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹46.03 Billion | +11.83% |
| 2024-03-31 | ₹41.16 Billion | +1.65% |
| 2023-03-31 | ₹40.49 Billion | +20.53% |
| 2022-03-31 | ₹33.59 Billion | +29.16% |
| 2021-03-31 | ₹26.01 Billion | +46.95% |
| 2020-03-31 | ₹17.70 Billion | +13.56% |
| 2019-03-31 | ₹15.58 Billion | +5.11% |
| 2018-03-31 | ₹14.83 Billion | +11.44% |
| 2017-03-31 | ₹13.30 Billion | +56.19% |
| 2016-03-31 | ₹8.52 Billion | +18.17% |
| 2015-03-31 | ₹7.21 Billion | +101.12% |
| 2014-03-31 | ₹3.58 Billion | +38.23% |
| 2013-03-31 | ₹2.59 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Laurus Labs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5469.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹36.26 Billion | 81.08% |
| Common Stock | ₹1.08 Billion | 2.41% |
| Other Comprehensive Income | ₹53.80 Million | 0.12% |
| Other Components | ₹7.33 Billion | 16.39% |
| Total Equity | ₹44.73 Billion | 100.00% |
Laurus Labs Limited Competitors by Market Cap
The table below lists competitors of Laurus Labs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Konecranes Plc
PINK:KNCRF
|
$4.03 Billion |
|
Yunnan Chuangxin New Material Co Ltd
SHE:002812
|
$4.03 Billion |
|
Babcock International Group PLC
PINK:BCKIF
|
$4.03 Billion |
|
Temenos AG
PINK:TMNSF
|
$4.04 Billion |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
$4.02 Billion |
|
Keisei Electric Railway Co. Ltd.
PINK:KELRF
|
$4.01 Billion |
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
$4.01 Billion |
|
Shanghai Zhangjiang Hi-Tech Park Development Co Ltd
SHG:600895
|
$4.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laurus Labs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 41,109,500,000 to 44,725,600,000, a change of 3,616,100,000 (8.8%).
- Net income of 3,583,200,000 contributed positively to equity growth.
- Dividend payments of 431,300,000 reduced retained earnings.
- Share repurchases of 101,700,000 reduced equity.
- New share issuances of 101,700,000 increased equity.
- Other comprehensive income increased equity by 342,500,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹3.58 Billion | +8.01% |
| Dividends Paid | ₹431.30 Million | -0.96% |
| Share Repurchases | ₹101.70 Million | -0.23% |
| Share Issuances | ₹101.70 Million | +0.23% |
| Other Comprehensive Income | ₹342.50 Million | +0.77% |
| Other Changes | ₹121.70 Million | +0.27% |
| Total Change | ₹- | 8.80% |
Book Value vs Market Value Analysis
This analysis compares Laurus Labs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 150.59x to 11.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | ₹6.38 | ₹960.80 | x |
| 2014-03-31 | ₹8.08 | ₹960.80 | x |
| 2015-03-31 | ₹16.25 | ₹960.80 | x |
| 2016-03-31 | ₹17.31 | ₹960.80 | x |
| 2017-03-31 | ₹29.23 | ₹960.80 | x |
| 2018-03-31 | ₹27.88 | ₹960.80 | x |
| 2019-03-31 | ₹29.26 | ₹960.80 | x |
| 2020-03-31 | ₹33.18 | ₹960.80 | x |
| 2021-03-31 | ₹48.27 | ₹960.80 | x |
| 2022-03-31 | ₹62.15 | ₹960.80 | x |
| 2023-03-31 | ₹74.82 | ₹960.80 | x |
| 2024-03-31 | ₹76.18 | ₹960.80 | x |
| 2025-03-31 | ₹82.89 | ₹960.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laurus Labs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.01%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.45%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.09x
- Recent ROE (8.01%) is below the historical average (16.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 34.02% | 12.28% | 1.02x | 2.71x | ₹622.88 Million |
| 2014 | 19.08% | 5.15% | 1.04x | 3.55x | ₹325.27 Million |
| 2015 | 9.48% | 5.15% | 0.72x | 2.56x | ₹-37.17 Million |
| 2016 | 15.70% | 7.52% | 0.77x | 2.70x | ₹485.53 Million |
| 2017 | 14.30% | 9.99% | 0.72x | 1.99x | ₹572.31 Million |
| 2018 | 11.30% | 8.15% | 0.68x | 2.03x | ₹193.46 Million |
| 2019 | 6.02% | 4.09% | 0.69x | 2.14x | ₹-620.77 Million |
| 2020 | 14.42% | 9.01% | 0.76x | 2.12x | ₹782.92 Million |
| 2021 | 37.87% | 20.43% | 0.84x | 2.21x | ₹7.24 Billion |
| 2022 | 24.69% | 16.77% | 0.71x | 2.08x | ₹4.92 Billion |
| 2023 | 19.57% | 13.08% | 0.79x | 1.90x | ₹3.86 Billion |
| 2024 | 3.91% | 3.18% | 0.60x | 2.04x | ₹-2.51 Billion |
| 2025 | 8.01% | 6.45% | 0.59x | 2.09x | ₹-889.36 Million |
Industry Comparison
This section compares Laurus Labs Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laurus Labs Limited (LAURUSLABS) | ₹49.34 Billion | 34.02% | 0.91x | $4.02 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |